Home › Research › Tau biomarkers
Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease
Wang Y, Li F, Qin Q, Li T, Wang Q, Li Y, Li Y, Jia J et al.. The journal of prevention of Alzheimer's disease, 2025-01-17
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Apolipoprotein E ε4 (APOE ε4) bring the higher risk of Alzheimer' Disease (AD). It is essential to evaluate whether the diagnostic performances and critical values of cerebrospinal fluid (CSF) biomarkers are influenced by APOE ε4, which has guiding significance for the clinical practical application. Methods The differences in CSF biomarkers and their performances between APOE ε4 carriers and non-carriers in distinguishing AD, mild cognitive impairment (MCI) and preclinical AD from normal controls (NCs) were analyzed.
What this study adds
Evidence grade: Low
The record lists 1,610 participants. This study analyzed whether carrying the APOE ε4 risk gene changes how well cerebrospinal fluid biomarkers distinguish Alzheimer's disease, mild cognitive impairment and preclinical Alzheimer's from normal controls. It is about diagnostic test performance, not about treating, curing or preventing the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wang, Y., Li, F., Qin, Q., Li, T., Wang, Q., Li, Y., et al. (2025). Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease. The journal of prevention of Alzheimer's disease. https://doi.org/10.1016/j.tjpad.2025.100065
Vancouver
Wang Y, Li F, Qin Q, Li T, Wang Q, Li Y, et al. Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease. The journal of prevention of Alzheimer's disease. 2025. doi:10.1016/j.tjpad.2025.100065. PMID: 39827005.
BibTeX
@article{wang2025-39827005,
author = {Wang, Y. and Li, F. and Qin, Q. and Li, T. and Wang, Q. and Li, Y. and Jia, J. and others},
title = {{Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease}},
journal = {The journal of prevention of Alzheimer's disease},
year = {2025},
doi = {10.1016/j.tjpad.2025.100065},
pmid = {39827005},
url = {https://doi.org/10.1016/j.tjpad.2025.100065}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- It is essential to evaluate whether the diagnostic performances and critical values of cerebrospinal fluid (CSF) biomarkers are influenced by APOE ε4, which has guiding significance for the clinical practical application.
- Methods The differences in CSF biomarkers and their performances between APOE ε4 carriers and non-carriers in distinguishing AD, mild cognitive impairment (MCI) and preclinical AD from normal controls (NCs) were analyzed.
- The receiver operating characteristic (ROC) curves were generated to compare the area under the curve (AUC) between APOE ε4 carriers and non-carriers, as well as the critical values corresponding Youden Index.
- Results In a cross sectional convenience sample of 1610 participants, lower Aβ42 and Aβ42/Aβ40 and higher p-Tau 181/Aβ42 in CSF were observed among APOE ε4 carriers than non-carriers in NC, MCI, and AD groups (P< 0.05).
Why it matters
This study analyzed whether carrying the APOE ε4 risk gene changes how well cerebrospinal fluid biomarkers distinguish Alzheimer's disease, mild cognitive impairment and preclinical Alzheimer's from normal controls. It is about diagnostic test performance, not about treating, curing or preventing the disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants1,610
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,610 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Jianping Jia: h-index 61 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Capital Medical University: institution h-index 643 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39827005) |
| Free to read | 2 / 2 | Free to read |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.tjpad.2025.100065
- PubMed: 39827005
- Original source →
- Free full text: The Journal of Prevention of Alzheimer s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.